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Abstract. The number of published findings in biomedicine increases continually. 
At the same time, specifics of the domain’s terminology complicates the task of 
relevant publications retrieval. In the current research, we investigate influence of 
terms’ variability and ambiguity on a paper’s likelihood of being retrieved. We 
obtained statistics that demonstrate significance of the issue and its challenges, 
followed by presenting the sci.AI platform, which allows precise terms labeling as 
a resolution. 
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1. Key objectives of the study and its significance 
Over the last two decades, life sciences articles have become substantially more 
complex, reflecting technological evolution, particularly OMICs experimentation, 
increasing cooperation between multiple institutions, and involving more advanced 
math and statistics applied to the data. In many publications, plain unstructured text is 
supported by algorithms, code, and multiple files of processed and raw datasets with 
annotated metadata and graphs. With such enhancements in place, experimental 
articles, per se, might become a driving force of the Literature Based Discoveries 
(LBD) [1]. Recently, the whole field of “meta-analysis” has arose to describe “dry lab” 
studies on normalization, unification, and analysis of many similar datasets derived 
from different labs and projects. However, a number of experimental papers are 
missed, because they cannot be retrieved from the body of literature by keywords 
search. Needless to say that scientists are keenly interested in higher discoverability of 
their published research and referencing to their findings, as citation index becomes an 
increasingly prevalent metrics in evaluation of their work.  The issue can be addressed 
with proper semantic labeling of the texts as the very first step in global analysis of the 
research reports.   
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The state-of-the-art section reflects the ways published papers are algorithmically 
processed in text mining applications.  Such computations rely on preexisting, 
statistically supported information, while text mining of the scientific literature targets 
novel findings. This leads to Information Retrieval (IR) and then Information 
Extraction (IE) underperformance when applied to scientific literature.  
The objective of the paper is to consider just one issue of many in biomedical texts 
processing: false terms recognition caused by ambiguity of the concepts’ names and 
multiple-terms spelling variants. This leads to at least two undesirable effects:  
1. Lower recall rate when search engines and aggregators retrieve articles, so the 
target audience does not receive a full set of relevant papers. 
2. Retrieving a paper that is irrelevant to the sought-for concept. For example, 
reader can query ‘cat’ with the ‘cat’ animal in mind but receive texts about the ’CAT’ 
gene.  
We address: 
a. A global need of initial transformation of the plain text to a machine-readable 
format; and  
b. Uncertainty issue mentioned above;  
by releasing the sci.AI system. This system combines automatic metatagging and 
manual validation of the results by the author or reader and supports generating 
semantic structures during writing and editorial processing.  Human validation 
eliminates almost any possibility of term misinterpretation in the following IR and IE 
tasks, because authors can be expected to have a comprehensive understanding of the 
concepts being mentioned in their papers and can supervise the machine’s results. 
2. State of the art in the field of biomedical texts semanticization 
Computational Linguistics is one of the most dynamic fields with innovations being 
released almost monthly. Unfortunately, there is no solid state-of-the-art solution for 
biomedical text labeling yet that unites all the latest advances in each subfield into a 
single package.  
The first subfield is metatagging standards and paradigms. Semantic Web’s 
objects, concepts, knowledge association, and data representation utilize schema.org 
vocabularies and W3C RDF/XML [2]. A current limitation is the lack of a similar 
single schema for the life sciences. Former related initiatives here are W3C Scholarly 
HTML [11] and JATS4R [12]. Still both schemas do not provide a standard namespace 
for biomedical concepts labeling.  
The second subfield is terms labeling or Named Entities Recognition.  
Just as in many other areas, deep learning and neural networks (NN) methods are 
increasingly popular for extracting information from professional texts [7, 8]. NN 
algorithms are rather generic and can be applied for the text analysis in unsupervised 
fashion (i.e., to a variety of texts without establishing prior rules generation). However, 
its precision and recall hardy depend on statistical data and cannot be considered as 
stable solution for concepts and challenges that have appeared recently. Still, NN 
demonstrates the highest recognition rates [16, 17] among automatic methods.  
Then there are methods of increasing precision by reducing concepts ambiguity by 
connecting the same concepts in various ontologies.  
UMLS (Unified Medical Language System), in combination with MetaMap, 
provide graph-like links between objects from various ontologies, as widely-accepted 
solution for the Word Sense Disambiguation (WSD) task in the biomedical domain. 
Essentially, UMLS represents a metaontology of biomedical terms and concepts. 
UMLS is extensive and well supported by NIH, and it is in constant development. 
Future considerations include possibly connecting this data to the sci.AI application. 
Currently, there are several limitations:  
1. Lack of details for specialised ontologies, such as Uniprot and ChEBI. 
2. Focus on the indexing task for the NCBI. This leads to the same dropdown in 
precision and recall of post-publication text processing.  
3. It is not a simple plug-and-play solution for the publishing industry [6]. 
SciGraph by the Neo4j [13] framework allows objects to be interconnected and 
can be used as a technical basis for future metaontologies.  
3. Design and Methodology 
Resolving terms’ ambiguity and variability represents a significant challenge in text 
processing. Here, we investigated how these factors affect the paper’s influence. Such 
causality is assumed based on the logic that findings described in the paper can be 
reused and cited—only if the paper will be discovered by the readers first. To model 
paper’s influence potential mathematically, we defined Paper’s Influence as a function 
of a variable we called Discoverability. 
 𝑃𝑎𝑝𝑒𝑟′𝑠	𝐼𝑛𝑓𝑙𝑢𝑒𝑛𝑐𝑒	 = 	𝑓(𝑃𝑎𝑝𝑒𝑟′𝑠	𝐷𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑎𝑏𝑖𝑙𝑖𝑡𝑦) (1) 
 
The paper’s potential for influence greatly depends on how accurately search 
engines and aggregators solve the IR task. For further explanation, we will continue 
with our query scenario from above. A reader is discovering the paper about animal 
‘cat’ after querying string 𝑄: ‘genes of cat’, including term 𝑡:;  ‘cat’ while meaning 
biomedical concept 𝑐: ‘Felis catus’, corresponding to object ‘9685’ in the ontology 
[14]. Concept 𝑐: then can be referenced with any term (spelling variant) 𝑡:; of the set 𝑇: 
 𝑇: 	= 	 {𝑡:>, 𝑡:@, . . . , 𝑡:B} 	 ∈ 	 𝑐:	 (2) 
 
If we assume that a reader will read the paper if the search engine returned it in 
response to the query 𝑄:, then “discoverability” is a synonym of “retrieval”. We can 
then apply two major IR metrics, recall and precision:  
 𝑟𝑒𝑐𝑎𝑙𝑙	 = 	 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑎𝑙𝑙	𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡	𝑡ℎ𝑒	𝑐𝑜𝑛𝑐𝑒𝑝𝑡 = = 𝑃(𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	 ⊇ 𝑇:	|	𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠 ⊇ 𝑐:) (3) 
 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛	 = 	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠 = = 𝑃(𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑚𝑜𝑛𝑔	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑 ⊇ 𝑐:	|	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	 ⊇ 𝑇:) (4) 
 
As long as such cases could be found across biomedical terminology, when 
concept can have several synonyms (variable terms) or single term can refer to several 
concepts (ambiguous terms), probabilistic precision and recall can be calculated based 
on the numbers of possible outcomes when querying 𝑄: ⊇ 𝑡:;. For example, texts “TNF 
alpha”, “TNFa” and “TNF α” are variants of the object Uniprot [P01375]. This means 
that if search engine was queried with “TNF alpha”, an ideal result would return all 
documents that contain all three variants. Still, due to existence of the several variants, 
the there is a probability ≥ 0 that some of them will not be considered.  
We can estimate chances of such event using a basic definition of the probability 
as the ratio of the number of favorable outcomes to the total number of possible 
outcomes. Term’s ambiguity and variability define those numbers of possible 
outcomes. Finally, when we know precision and recall of the paper’s retrieving while 
searching for the concept 𝑐:, we can answer specific questions about discoverability of 
the paper in some kind of progression order. 
Question 1. How many papers out of all existing literature about concept 𝑐: can be 
retrieved, when there is set 𝑇:, all terms of which refer to this concept 𝑐: ? 
 𝑟𝑒𝑐𝑎𝑙𝑙(𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦)= 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:>	+	. . .		+	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑		𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:B	𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡	𝑐:	 == 𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑇:	𝑡𝑜𝑡𝑎𝑙	𝛴	𝑝𝑎𝑝𝑒𝑟𝑠	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡		𝑐:	 
(5) 
 
Question 2. How many papers out of retrieved and containing terms from 𝑇: 
mention concept 𝑐:specifically? As long as only recorded synonyms are proved to 
exist, we can assume that all synonyms from the ontology and generated variants 
constitute a full dictionary of the concept, and  
 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛(𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦)= 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐:	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:>	+	. . . +	𝑛𝑢𝑚𝑏𝑒𝑟	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:B	 = = 𝛴	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑜𝑢𝑡	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡	𝑐:	𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑇:	 , ∀𝑡:;, 𝑇: 	 ∈ 	 𝑐: , ⇒ 𝛴	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑐: 	= 𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑇: 	⇒  ⇒ 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛(𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 	= 1 
(6) 
 
This means that precision for the specific concept does not depend on the number 
of variants, as long as we assume that all variants are describing the same concept in 
the event.  
Question 3. There is term 𝑡:;which refers to the concept 𝑐: or another concept 𝑐R. 
How many papers out of retrieved and containing term 𝑡:;, are talking about the 
concept 𝑐:exactly?  
 
 
 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = = 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐:	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐:	+	. . . +	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔		𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐R	 = (7) 
= 𝛴	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑜𝑢𝑡	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐:	𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠		𝑐: ∩. . .∩ 	𝑐R = {𝑡:;}	  
 
Question 4. Did we receive all papers containing term 𝑡:;? (Answer: Yes, 
obviously. Continuing to ask this question is important for keeping track of the general 
recall and precision derivation) 
 𝑟𝑒𝑐𝑎𝑙𝑙(𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦) = 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:;𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑡:;	 = 1 (8) 
 
Question 5. What is the overall probability of retrieving a relevant paper for the 
concept 𝑐: that has many variants {𝑡:>, 𝑡:@, . . . , 𝑡:B} and some of them 	𝑐: ∩. . .∩ 	𝑐R ={𝑡:;} are also found in the other concepts?  
This means a probability of two independent events: A = the concept has spelling 
variants, and B = those variants can be found in several concepts. Therefore P (A and 
B) will be multiples of the probabilities above:  
 𝑟𝑒𝑐𝑎𝑙𝑙 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	𝑎𝑛𝑑	𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = 𝑟𝑒𝑐𝑎𝑙𝑙 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 ∗ 𝑟𝑒𝑐𝑎𝑙𝑙 𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = = 𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑤𝑖𝑡ℎ	𝑇:	𝑡𝑜𝑡𝑎𝑙	𝛴	𝑝𝑎𝑝𝑒𝑟𝑠	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡		𝑐:	 ∗ 1 (9) 
 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	𝑎𝑛𝑑	𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = = 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 ∗ 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = = 𝛴	𝑟𝑒𝑙𝑒𝑣𝑎𝑛𝑡	𝑜𝑢𝑡	𝑜𝑓	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠	𝑎𝑏𝑜𝑢𝑡		𝑐:	𝛴	𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑	𝑝𝑎𝑝𝑒𝑟𝑠		𝑐: ∩. . .∩ 	𝑐R = {𝑡:;}	 ∗ 1 (10) 
   
If operating only with the number of variants per concept, then prior probability of 
variants occurrence can be approximated as uniformly distributed, as long as actual 
frequency of terms occurrence in the papers will be retrieved in the next steps. This 
means that, in the first approximation, occurrence = {True, False} of the term can be 
sufficient variable to estimate the minimum expected probabilities:  
 𝑝𝑟𝑖𝑜𝑟	𝑟𝑒𝑐𝑎𝑙𝑙(𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	𝑎𝑛𝑑	𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦) = 1	𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑡𝑒𝑟𝑚𝑠	𝑣𝑎𝑟𝑖𝑎𝑛𝑡𝑠	𝑝𝑒𝑟	𝑐𝑜𝑛𝑐𝑒𝑝𝑡	 (11) 
 𝑝𝑟𝑖𝑜𝑟	𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	𝑎𝑛𝑑	𝑎𝑚𝑏𝑖𝑔𝑢𝑖𝑡𝑦 = = 1𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑜𝑛𝑐𝑒𝑝𝑡𝑠	𝑝𝑒𝑟	𝑠𝑖𝑛𝑔𝑙𝑒	𝑡𝑒𝑟𝑚	𝑣𝑎𝑟𝑖𝑎𝑛𝑡 (12) 
 
As long as the Number of the terms per concept ≥ 1 (each object has at least a 
main name) and Number of concepts per single term variant ≥ 1 (each term is related to 
at least one object) and they are in the denominator of the retrieving probabilities 
above—terms’ variability and ambiguity will always reduce (at least, will not increase) 
recall and precision, respectively, when searching for the paper.  
In order to estimate influence of the existing terms’ uncertainty on the papers 
discoverability, we have searched for:  
1. homographs across Uniprot, ICD-10, ChEBI, MeSH, Drugbank, and Gene 
Ontology databases;   
2. possible spelling variants for the same objects;   
3. actually used terms’ variants in the 26782464 Pubmed, 26404 Bioline and 5426 
eLife papers. 
MeSH Categories G–Z were not analysed because they contain generic objects, 
such as countries’ names, which are out of scope of sci.AI semanticization for now. 
Our research is ongoing and the latest results can be found on the sci.AI webpage 
[20]. 
 
Table 1. Variability in the ontologies and influence on paper’s recall 
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Uniprot 553667 1018837 1.8402 702942 1729359 3.1235 936673 84 0.0119 
ChEBI 104854 201061 1.9175 175750 510817 4.8723 67159 81 0.0123 
Gene 
Ontology 
46517 173156 3.7224 47073 287903 6.1914 54711 94 0.0106 
Drugbank 8221 28980 3.5251 15724 154704 18.8204 28445 243 0.0041 
ICD-10 11420 20728 1.8150 9680 30463 2.6675 14883 19 0.0526 
MeSH  
(A-F tree) 
23716 199486 8.4114 139078 309189 13.0459 170898 210 0.0048 
 
We had not only considered synonyms that exist in the ontologies but also created 
a rules-based term variant generator (TVG) to cover a case when the same object, 
Uniprot [P01375], might be written as “TNF alpha”, “TNFa”, or “TNF α” in a paper. 
Next generating techniques groups were utilized: 
- orthographic; 
- abbreviations and acronyms;  
- inflectional variations; 
- morphological variations;  
- structural recombinations [4, 5, 6].   
Table 1 shows average number of original terms’ synonyms and how much 
variants were generated. Then we’ve searched for them in the papers. There is increase 
of the concept detection of 2.03 - 3 times more when searching for all variants. 
Table 2 shows how much objects has terms with identical spellings, i.e. ambiguous 
terms. Higher overlap within the same ontology than across other ontologies makes 
algorithmic recognition even more challenging tasks, because algorithms have to 
distinguish objects within the same class. 
 
 
 
Table 2. Ambiguity in the ontologies and influence on paper’s precision 
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Fig.1 shows overall influence of the variability and ambiguity of the terminology 
on paper’s discoverability.  
 
 
a) Uniprot 
 b) ChEBI 
 
c) GeneOntology 
 d) DrugBank 
 
e) ICD10 
Figure 1. Influence of the terminology variability and ambiguity on a paper retrieval when text contains 
proteins, chemical elements, genes, drugs, diseases.  
 
 
When searching by original synonyms only, average likelihood of finding papers is 
lower than searching by all possible variants. Retrieving higher amount of the papers 
can be done at the cost of their relevance. Increasing amount of variants leads to the 
drop of the probabilistic precision. Relevance can be guaranteed only in case of 
labeling terms and searching by exact ID instead of a string. As long as current 
literature is not labeled, exact recall and precision can’t be calculated for. We used 
relative changes instead, to visualize scale of the issue across most of the available 
literature. 
Fig.2 shows the distribution of the variability across ontologies.  
 
 
a) Uniprot 
 b) ChEBI 
 
c) GeneOntology 
 
d) DrugBank 
 
e) ICD10 
 
f) MeSH 
Figure 2. Number of objects that have specific amounts of original synonyms, generated variants and 
variants found in the papers. 
There are original synonyms in the ontologies, generated variants and how much 
of them were found in the papers. It shows that there are significant chances to found 
term’s spelling that was never mentioned in the ontology. Thus, it reduces recall of the 
relevant papers. 
We were going to use the MSH WSD Data Set [15] initially for the ambiguity 
testing purposes, but it turned out to contain generic words only. So, we performed a 
generic wide search across all ontologies and variants to obtain low-level detalization.  
There is also a case of “artificial” ambiguity in ontologies. It is caused by 
intersection of alternative names and terms’ descriptions in attempt of extending 
variants to increase recall. “Carbon monoxide” example is provided in the Table 3.  
 
Table 3. Example of the objects with the same spelling.  
Primary 
name 
Ontology Matched Objects Synonyms 
Carbon 
monoxide 
ICD10 Accidental poisoning 
by and exposure to 
other gases and 
vapours (X47) 
utility gas, utility ga, helium, motor exhaust ga, 
accidental poisoning by and exposure to other 
gases and vapours, sulfur dioxide, lacrimogenic 
gas, carbon monoxide, motor exhaust gas, 
nitrogen oxides 
Intentional self-
poisoning by and 
exposure to other 
gases and vapours 
(X67) 
utility gas, intentional self-poisoning by and 
exposure to other gases and vapours, helium, 
sulfur dioxide, lacrimogenic gas, carbon 
monoxide, motor exhaust gas, nitrogen oxides 
Poisoning by and 
exposure to other 
gases and vapours, 
undetermined intent 
(Y17) 
poisoning by and exposure to other gases and 
vapours, undetermined intent, utility gas, helium, 
sulfur dioxide, lacrimogenic gas, carbon 
monoxide, motor exhaust gas, nitrogen oxides 
MeSH Carbon Monoxide 
(D002248) 
carbon monoxide, monoxide, carbon 
ChEBI carbon monoxide 
(CHEBI:17245) 
carbon monoxide, CO 
Drugbank Carbon monoxide 
(DB11588) 
carbon monoxide, lung diffusion test mix nohco, 
lung diffusion test mixture, lung diffusion test 
mixture gas, carbon monoxide, compressed air 
medical G.M., lung diffusion test mix no Ne Co, 
carbon(II) oxide, Co-HE-O2-N2 mixture, 
carboneum oxygenisatum, Co-NE-O2-N2 mixture, 
carbon monox, helium, oxygen, nitrogen L.D.M., 
CO 
CH GeneOntology naringenin-chalcone 
synthase activity 
(GO:0016210) 
CH, malonyl-coa:4-coumaroyl-coa 
malonyltransferase(cyclizing), chalcone synthase 
activity, chalcone synthetase activity, naringenin-
chalcone synthase activity, flavanone synthase 
activity, DOCS, flavonone synthase activity, 
DOC, CHS 
Uniprot Cheilanthifoline 
synthase 
(C7195_ESCCA) 
CH, CHS, cytochrome P450 719A5, 
cheilanthifoline synthase 
Canavanine 
hydrolase 
(CANHY_HELVI) 
CH, canavanine hydrolase 
ChEBI methanylylidene 
group 
(CHEBI:29432) 
CH, methanylylidene group 
methylidyne group 
(CHEBI:29429) 
CH, methylidyne group 
methanetriyl group 
(CHEBI:29433) 
CH, methanetriyl group 
Drugbank N-Cyclohexyltaurine 
(DB03309) 
CHES, n-cyclohexyltaurine, CH 
IMP MeSH = ChEBI Inosine 
Monophosphate 
(D007291) 
ribosylhypoxanthine monophosphate, inosinic 
acid, IMP, inosinate, sodium, sodium inosinate, 
inosine monophosphate, acids, inosinic, 
monophosphate, ribosylhypoxanthine, inosinic 
acids, monophosphate, inosine, acid, inosinic 
DrugBank Imipenem 
(DB01598) 
imipemide, imipenem anhydrou, imipenem 
anhydrous, n-formimidoylthienamycin, imipenem, 
IMP, imipenem and cilastatin for injection, USP, 
ran-imipenem-cilastatin, imipenem, n-
formimidoyl thienamycin, imipenem and 
cilastatin, imipenemum, imipenem and cilastatin 
for injection, -USP, primaxin 250, imipenem and 
cilastatin for injection USP, (5R,6S)-6-((R)-1-
Hydroxyethyl)-3-(2-(iminomethylamino) 
ethylthio)-7-oxo-1-azabicyclo(3.2.0) hept-2-ene-2-
carbonsaeure, primaxin IV 500, primaxin 500, 
primaxin IV 250/250 add-vantage vial, imipenem 
and cilastatin for injection, usp, imipenem and 
cilastatin for injection,-usp, (5R,6S)-3-(2-
formimidoylamino-ethylsulfanyl)-6-((R)-1-
hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0] hept-2-
ene-2-carboxylic acid, imipenem and cilastatin for 
injection, tienamycin, imipenem and cilastatin for 
injection usp, imipenem and cilastatin for 
injection-USP, imipenem and cilastatin for 
injection-usp, primaxin IV, primaxin-iv, n-
formimidoyl thienamycin, (5R,6S)-3-((2-
(formimidoylamino) ethyl) thio)-6-((R)-1-
hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0) hept-2-
ene-2-carboxylic acid 
GeneOntology. 
The same 
obsolete 
mitochondrial inner 
IMP, obsolete mitochondrial inner membrane 
peptidase activity, mitochondrial inner membrane 
membrane peptidase 
activity 
(GO:0004244) 
peptidase activity 
mitochondrial inner 
membrane peptidase 
complex 
(GO:0042720) 
IMP, mitochondrial inner membrane peptidase 
complex 
ChEBI IMP (CHEBI:17202) IMP, C10H13N4O8P 
Uniprot.  
The same for 
various 
organisms 
Inositol 
monophosphatase 
(IMPA1_DICDI) 
IMPase, IMP, inositol-1(or 4)-monophosphatase, 
inositol monophosphatase, d-galactose 1-
phosphate phosphatase 
Inositol 
monophosphatase 
(IMPP_MESCR) 
IMPase, IMP, inositol-1(or 4)-monophosphatase, 
inositol monophosphatase 
Inositol 
monophosphatase 
ttx-7 
(IMPA1_CAEEL) 
IMPase, IMP, inositol monophosphatase ttx 7, 
abnormal thermotaxis protein vii, inositol-1(or 4)-
monophosphatase, abnormal thermotaxis protein-
7, inositol monophosphatase ttx vii, inositol 
monophosphatase ttx-vii, abnormal thermotaxis 
protein7, d-galactose 1-phosphate phosphatase, 
abnormal thermotaxis protein 7, inositol 
monophosphatase ttx-7, abnormal thermotaxis 
protein-vii, inositol monophosphatase ttx7 
 
 
This leads to the necessity of human validation of the same concepts identification. 
Such functionality exists in sci.AI to validate several ID’s from the various ontologies 
for the same term (Fig. 3). 
4. Decreasing retrieving uncertainty with the precise semantic labeling feature of 
the sci.AI platform 
Formalization and statistics above show that uncertainty is not an exception but basic 
feature of the biomedical text mining. This uncertainty might lead to significant 
deviations when interpreting academic papers with unsupervised methods only. While 
it might be acceptable for fiction literature mining, because the major task there is 
context and sentiments analysis that acts as a smoothing function—such uncertainty 
might contradict goals of mining STEM research communication, where we are 
looking for the anomalistic or novel discoveries, exact objects interactions, verification 
of facts, and relations between statements in various texts. This is why accepting 
uncertainty might have significant negative consequences on the LBD. 
 
 
Figure 3. Labeling term with several objects. 
 
 
In order to address this issue, we implemented the sci.AI platform that has 
supervised labeling functionality on top of the text mining framework. After initial 
automatic terms recognition, no matter whether precision is 70% or 99%, users can 
make final verifications to level up recognition precision to 100%. From the 
perspective of the search and text mining algorithms, this means removing any 
uncertainty, which, in turn, leads to exact papers extraction in an SQL-like querying 
manner. Thus, assuming that author will always label terms correctly, maximum 
precision and recall will be achieved.  
Human-made corrections will be used as training data for the next processings of a 
text. Such learning with human feedback provides steady path to gradient growth of 
text mining quality.  
Current version of the sci.AI allows to upload text, then performs Named Entities 
Recognition (NER) task automatically. Author or annotator can validate labeling 
results via interface and export final structured text to the XML file (Fig.4).  
 
 
Figure 4. Paper semanticization in sci.AI. 
 
Development roadmap includes release of the next features:  
- Machine Learning based analysis to provide the most likeable variants in the first 
place. This feature will be based on the (a) logs of the terms validation events and (b) 
statistical co-occurrences of the terms in all available texts. We expect that it will 
provide approximately 90% recognition rate, as reported by NN researchers [7, 8]. 
Introduction of the NN prioritisation is expected to reduce cases of the necessary 
authors intervention to the reasonable minimum. Internal time tracking done by our 
team members suggest that 10 pages validation time will be reduced from 1 h to 15 
min, approximately. Current statistics will be corrected after actual feature release and 
making more measures for the various annotators and texts with different density of the 
terms;  
- Graph based WSD connections between objects and existing metaontologies 
data;  
- Generating JATS, RDF/XML and RDFa files;  
- Validation by the readers, not only by the authors;  
- Concepts interactions labeling, for example, protein-protein.  
The system can be embedded into the publishing process directly. Both authors 
and editors can create semanticized versions during submission of even publish new 
version of the digital paper.  Key features of the current production version are as 
follows:  
1. Automated metatagging of biomedical concepts, (named-entity recognition, 
with further context-dependant semanticization of terms). Current tags contain links to 
the related objects in the ontology; 
2. User-friendly web preprint for tags editing and recognition supervising;  
3. Web application for easy integration into the existing publishing process.   
sci.AI allows labeling a term with several term-2-ontologyId relationships. For 
example, ‘serotonin’ is the object UID=D012701 in MeSH and UID=28790 in ChEBI 
ontologies simultaneously. Author or reader can suggest additional UIDs too or can 
correct existing one. This functionality contributes to the global connectivity between 
terms and might support UMLS Word Sense Disambiguation (WSD) works.  
We expect another possible positive effect for the future papers too. Authors might 
come to the same single spelling variant of the concept, like “ClNa” only and not “salt” 
or “NaCl”. 
As of the end of 2016, sci.AI is in the first phases of its long-term development 
roadmap from being a semanticization tool to becoming a full-fledged artificial 
intelligence (AI) tool applied to the life sciences. Wide adoption of this application will 
extend the publisher's role even further into research results delivery to the intended 
target audience.  
5. Discussion 
This paper is the first in our series of researchers about precise semantic labelling of 
life sciences texts. Our goal was to focus on dependency of the paper’s influence on 
two fundamental factors: ambiguity and variability of terms. In order to avoid 
excessive complication, we made several assumptions which may bias the results. 
These simplifications will be addressed in follow-up studies: 
1. Prior precision estimation is calculated with assumption that probability of 
retrieving a paper with concept 𝑐: when searching for ambiguous term 𝑡: might have 
uniform distribution. In fact, it has a nonlinear distribution, as shown in statistics in 
Tables 1, 2 and Fig. 2. 
2. Prior recall estimation is calculated with assumption that probability of 
retrieving a paper with concept 𝑐: when searching for term 𝑡: with multiple variants 
might have uniform distribution. In fact, it has a nonlinear distribution as shown in 
statistics in Table 1, 2 and Fig. 2. 
3. Simplified dependency of recall from ambiguity and precision from variability. 
4. Categories of terms variability and implementation of the terms variant 
generator deserve full comprehensive description in the following research.  
6. We intended to show fundamental specifics of biomedical language that makes 
it is challenging to achieve 100% recognition of terms with unsupervised methods only. 
Still, there are various NLP approaches including metaontologies like UMLS based 
disambiguation and statistical methods that significantly improve terms recognition. 
Those methods are integrated by sci.AI development team and performance of each of 
them will be evaluated in separate paper.  
7. We assumed that there is the same number of concepts and objects within single 
ontology.  
8. “Human factor” was removed from consideration by assuming that author can 
always correctly label every biomedical concept in own manuscript. Under “precise 
labeling” we mean “labeling verified by the actual text’s author”. 
9. There are several studies, where researchers propose models of the future 
paper’s success, for example, [19]. Future analysis might take into consideration 
ambiguity and variability as variables in the prediction models.  
10. Part of speech tagging might improve precision of the variants validation. This 
functionality exists in the sci.AI but was not applied for the statistics calculation.  
11. We assume that all possible spelling variants were generated. Further 
validation is required.  
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Appendix A. Examples of the objects’ synonyms and generated variants 
Variants, that were found in actual papers are marked with * and DOI of one of the 
retrieved papers. 
 
Primary term: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
Ontology: Uniprot [PRGC1_HUMAN] 
Synonyms: PGC-1-alpha, PPAR-gamma coactivator 1-alpha, PPARGC-1-alpha, Ligand effect modulator 6 
Variants: *PGC-1alpha [10.1186/1750-1326-4-10], PPARGC 1-alpha, *PPAR γ-coactivator 1α 
[10.1038/nutd.2011.3], *peroxisome proliferator-activated receptor-γ-coactivator 1-α 
[10.1016/j.molmet.2015.09.003], PPARGC-i-α, *PPAR-gamma coactivator 1α [10.1186/1476-511X-10-
246], *PPARGC1-α [10.1186/1743-7075-7-88], *PPAR-gamma coactivator 1alpha [10.1155/2008/418765], 
*peroxisome proliferator-activated receptor γ coactivator 1-alpha [10.1038/srep18011], *peroxisome 
proliferator-activated receptor-γ-coactivator 1α [10.1210/me.2014-1164], *PPAR γ coactivator 1 α 
[10.1074/jbc.M115.636878], *peroxisome proliferator-activated receptor γ coactivator 1-α 
[10.1016/j.molmet.2015.09.003], PGC-i-α, *PGC-1 α [10.1038/ncomms10210], *PPAR-γ-coactivator 1-
alpha [10.1371/journal.pone.0055940], *PGC-1α [10.7554/eLife.03245], *ligand effect modulator-6, 
PPARGC i-α, *PPARGC-1 α [10.1074/jbc.M113.512483], PPARGC ialpha, *PPAR-gamma coactivator 1 α 
[10.3892/mmr.2013.1714], *PPAR-γ coactivator 1 α [10.1074/jbc.M115.636878], PPAR γ coactivator 
1alpha, *ligand effect modulator 6, PGC-i alpha, *peroxisome proliferator-activated receptor-γ-coactivator 1 
alpha [10.1038/srep18011], *PPAR-γ coactivator 1α [10.1038/nutd.2011.3], *PPARGC 1alpha 
[10.1038/nm.2049], PPARGC-ialpha, *peroxisome proliferator-activated receptor γ coactivator 1alpha 
[10.1111/jnc.12089], PGC iα, ligand effect modulator6, *peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha [10.1152/ajpgi.00270.2015], *PPARGC 1 α [10.1074/jbc.M113.512483], PGC-i α, 
*PPAR-γ-coactivator 1 α [10.1074/jbc.M115.636878], *PGC1-α [10.7150/ijbs.7972], *PGC 1α 
[10.7554/eLife.03245], PPARGC iα, *PPARGC1 alpha [10.1016/j.jnutbio.2009.03.012], *PGC1-alpha 
[10.2527/jas.2009-1896], *PPARGC1-alpha [10.1016/j.jnutbio.2009.03.012], *PGC1α 
[10.1016/j.molmet.2015.08.002], *peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
[10.1152/ajpgi.00270.2015], *PPAR-γ coactivator 1 alpha [10.1371/journal.pone.0055940], ligand effect 
modulator vi, *peroxisome proliferator-activated receptor γ coactivator 1 alpha [10.1038/srep18011], 
*PPARGC 1α [10.1371/journal.pgen.1005062], PPARGC-i α, PPARGC i-alpha, *peroxisome proliferator-
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